文献速递技术与安全PETCT

18F-FDG PET/CT在脾边缘区淋巴瘤中的应用

18F-FDG PET/CT in splenic marginal zone lymphoma.
PubMed 文献 · Abdom Radiol (NY) · 2018-01-01

研究纳入51例组织学确诊的脾边缘区淋巴瘤患者,于初始分期时行18F-FDG PET/CT,视觉与半定量分析显示76%患者FDG高摄取,弥漫性脾摄取为主要表现,FDG高摄取仅与Ki-67指数相关,无进展生存期不受FDG高摄取影响。

要点

  • 76%的脾边缘区淋巴瘤在18F-FDG PET/CT上呈FDG高摄取,弥漫性脾摄取为主要表现。
  • FDG高摄取仅与Ki-67指数显著相关,与年龄、性别、浆细胞分化及脾最大径无关。
  • FDG高摄取状态未影响无进展生存期。

核心结论

  • 76%的脾边缘区淋巴瘤呈FDG高摄取,以弥漫性脾摄取为主要表现,FDG高摄取仅与Ki-67评分相关,未影响无进展生存期。

研究设计与样本

  • 纳入51例组织学确诊的脾边缘区淋巴瘤患者(34例男性、17例女性,平均年龄70岁),于初始分期时行18F-FDG PET/CT,图像行视觉与半定量分析(SUVmax、病灶/肝脏SUVmax比值、病灶/血池SUVmax比值)。

诊断标准与关键数值

  • 39例(76%)为FDG高摄取脾边缘区淋巴瘤,其中7例为局灶性脾病灶、32例为弥漫性脾摄取,其余12例脾摄取无增高;FDG高摄取病灶的平均SUVmax为4.3,病灶/肝脏SUVmax比值为2.3,病灶/血池SUVmax比值为3。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The detection rate and the metabolic behavior of 18F-FDG-PET/CT in splenic marginal zone lymphoma (SMZL) are not yet clear. Our aim was to investigate the metabolic behavior of SMZL and whether the tumor stage (acc. Ann Arbor) epidemiological (age, gender), histological (Ki-67 index, plasmacytic differentiation), and morphological (splenic diameter maximum) features might be related to 18F-FDG PET/CT results.

METHODS: Fifty-one patients (34 male, 17 female; average age 70 years) with histologically confirmed SMZL who underwent a 18F-FDG PET/CT for initial staging were included: PET/CT images were analyzed visually and semi-quantitatively (SUVmax, lesion-to-liver SUVmax ratio, and lesion-to-blood pool SUVmax ratio). Splenic uptake was divided as diffuse or focal.

RESULTS: Thirty-nine patients (76%) had FDG-avid SMZL (7 with focal splenic lesions and 32 with diffuse splenic uptake), while the remaining 12 had no increased splenic uptake. Among patients with FDG-avid lesions, average SUVmax was 4.3, lesion-to-liver SUVmax ratio 2.3, and lesion-to-blood pool SUVmax ratio 3. 18F-FDG avidity was significantly associated with Ki-67 index and not correlated with other features. Semiquantitative PET/CT parameters (SUVmax, lesion-to-liver SUVmax ratio, and lesion-to-blood pool SUVmax ratio) did not correlate significantly with any variable. Progression-free survival time was not influenced by FDG avidity of SMZL.

CONCLUSIONS: 18F-FDG avidity was noted in 76% of SMZL with diffuse splenic uptake as main pattern of presentation and is correlated with Ki-67 score only.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Albano D, Giubbini R, Bertagna F, et al. 18F-FDG PET/CT in splenic marginal zone lymphoma. Abdom Radiol (NY). 2018. PMID: 29500652. doi:10.1007/s00261-018-1542-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。